Project CADENCE (CAncer Detected Early caN be CurEd)
Study Details
Study Description
Brief Summary
With existing evidence showing the difference in miRNA expression levels between non-cancer and cancer groups, the investigators assume that levels of DNA methylation, RNA expression as well as protein concentration will also be dysregulated during disease progression. Combining the power of multi-omic cancer biomarkers, the investigators hypothesize that the sensitivity and specificity of MiRXES MCST can be significantly improved compared to existing multi-cancer diagnostic tests.
In this study, the investigators propose to develop and validate blood-based, multi-cancer screening tests through a multi-omics approach.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
This study consists of four (4) objectives:
-
Characterize intra-cellular multi-omic profiles of cancer and adjacent normal tissues to aid the selection of circulating cancer biomarkers.
-
Select and verify circulating multi-omic cancer biomarkers by characterizing the circulating multi-omic profiles of the peripheral blood of cancer patients, high-risk, increased-risk, and healthy controls, guided by tissue-based cancer omics profiles.
-
Develop multi-cancer screening in vitro diagnostic assay(s) based on the selected blood-borne circulating multi-omic cancer biomarker panel(s) and build algorithm(s) to distinguish cancer cases from control groups.
-
Clinically validate the performance (AUC, sensitivity, specificity) of the multi-cancer screening assay(s) and algorithm(s)
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Healthy average-risk cohort Individuals representing the general population who self-declare to have no cancer history and have no indications suggestive of underlying cancer development. Subjects will be recruited from a state-of-the-art population study. |
|
| Increased-risk (genetic/familial) cohort Individuals carrying certain germline mutations that predispose the subjects to an increased risk of having cancer than the general population. Subjects will be recruited from Cancer Genetics Service (CGS). |
|
| High-risk cohort Individuals diagnosed with diseases that have a high risk of progressing to cancer. A total of 600 subjects (200 subjects for each Phase 1B, 1C, and 1D) will be recruited by the lead PI of each cancer type. |
|
| Malignant cohort Individuals diagnosed with cancer. A total of 600 subjects (200 subjects for each Phase 1B, 1C, and 1D) will be recruited by the lead PI of each cancer type. Wherever possible, samples for the 'Malignant group' should have a representation of each cancer stage. |
Outcome Measures
Primary Outcome Measures
- To discover novel intracellular RNA and methylated DNA cancer biomarkers in fresh frozen tumor tissues. [through study completion, an average of 2.5 years]
- To select the best-performing multi-omic single-cancer, biomarker panels for each of the cancer types, and develop the corresponding Single-Cancer Early detection Algorithms (SCEAs). [through study completion, an average of 2.5 years]
- To discover and validate novel cell-free RNA and methylated cell-free DNA cancer biomarkers in the peripheral blood of cancer patients. [through study completion, an average of 2.5 years]
- To develop the best-performing multi-omic multi-cancer biomarker panel by integration and/or optimization of single-cancer panels and develop the corresponding Multi-Cancer Early detection Algorithm (MCEA). [through study completion, an average of 2.5 years]
- To develop in vitro diagnostic assay(s) for the Multi-Cancer Screening Test (MCST) and if appropriate Single-Cancer Screening Tests (SCSTs). [through study completion, an average of 2.5 years]
- To evaluate the clinical performance (AUC, sensitivity, specificity, tissue of origin) of the MCST and if appropriate SCSTs to discriminate cancer cases from control groups. [through study completion, an average of 2.5 years]
Secondary Outcome Measures
- Secondary outcome: • To explore the relationship between MCST/SCSTs with clinical outcomes based on the collection of longitudinal follow-up information from medical records. [through study completion, an average of 2.5 years]
Eligibility Criteria
Criteria
Inclusion Criteria:
Healthy average-risk cohort Individuals representing the general population who self-declare to have no cancer history and have no indications suggestive of underlying cancer development. Subjects will be recruited from a state-of-the-art population study.
Increased-risk (genetic/familial) cohort Individuals carrying certain germline mutations that predispose the subjects to an increased risk of having cancer than the general population. Subjects will be recruited from Cancer Genetics Service (CGS).
High-risk cohort Individuals diagnosed with diseases that have a high risk of progressing to cancer. A total of 600 subjects (200 subjects for each Phase 1B, 1C, and 1D) will be recruited by the lead PI of each cancer type.
Malignant cohort Individuals diagnosed with cancer. A total of 600 subjects (200 subjects for each Phase 1B, 1C, and 1D) will be recruited by the lead PI of each cancer type. Wherever possible, samples for the 'Malignant group' should have a representation of each cancer stage.
Exclusion Criteria:
Pregnant or lactating (self-declaration), unwilling or unable to provide signed informed consent and has or had received chemotherapy or radiotherapy for cancer treatment and/or any other cancer-related treatment.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Biopollis, Helios | Singapore | Singapore | 258710 |
Sponsors and Collaborators
- MiRXES Pte Ltd
Investigators
- Study Director: Cheng He, PhD, MiRXES Pte Ltd
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- MX-011-219